Ki-67与非小细胞肺癌患者EGFR突变的关系及其对预后的影响

摘要
图/表
参考文献(20)
相关文章 (6)

全文: PDF (549 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨Ki-67LI值与非小细胞肺癌患者表皮生长因子受体（EGFR）基因突变的关系及预测价值，分析Ki-67LI值对非小细胞肺癌患者生存期的影响。方法回顾性分析武汉大学人民医院2015年7月~2016年7月经病理证实为非小细胞肺癌患者并行EGFR突变检测的共100例，分析Ki-67LI值与EGFR突变关系及其与患者预后的关系。结果行EGFR突变检测共100例，其中发生突变共57例，突变率为57%。女性、非吸烟以及病理类型为腺癌的患者更容易出现EGFR突变（P < 0.01），EGFR突变情况与Ki-67有关，Ki-67LI值升高更易出现在EGFR突变阳性患者中（P < 0.05），并且Ki-67LI值是影响非小细胞肺癌患者预后的独立因素（OR=2.503；95%CI：1.077~5.815；P=0.033）。结论 Ki-67LI值可以预测非小细胞肺癌患者的预后，并且与非小细胞肺癌患者EGFR突变相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张煜坤戈伟

关键词 ：非小细胞肺癌, Ki-67, EGFR突变, 预后

Abstract：Objective To investigate the relationship between Ki-67LI and EGFR gene mutation in non-small cell lung cancer (NSCLC), as well as to further analyze the effect of Ki-67LI on the survival of patients with non-small cell lung cancer (NSCLC). Methods From July 2015 to July 2016, total of 100 patients with non-small cell lung cancer were treated in Renmin Hospital of Wuhan University. And 100 patients were examined by EGFR mutation. The relationship between Ki-67LI and EGFR mutation and its relationship with prognosis were investigated. Results A total of 100 cases were detected by EGFR mutation, among them, 57 cases were mutated and the mutation rate was 57%, the incidence of which was more frequent in women, non-smokers, adenocarcinoma patients (P < 0.01), and also found that EGFR mutations were associated with Ki-67, Ki-67LI values were more likely to occur in patients with EGFR mutations-positive (P < 0.05), and Ki-67LI was also an independent factor in the prognosis of patients with non-small cell lung cancer (OR=2.503, 95%CI: 1.077-5.815, P=0.033). Conclusion The value of Ki-67LI can independently predict the prognosis of non-small cell lung cancer patients, which is has a close relationship with EGFR mutations.

Key words： Non-small cell lung cancer Ki-67 EGFR mutation Prognosis

基金资助:国家重点研发计划项目（2016YFC1303800）

引用本文:

张煜坤戈伟. Ki-67与非小细胞肺癌患者EGFR突变的关系及其对预后的影响[J]. 中国医药导报, 2017, 14(32): 79-81,85.
ZHANG Yukun GE Wei. Relationship between Ki67 and EGFR mutations and prognosis in non-small cell lung cancer. 中国医药导报, 2017, 14(32): 79-81,85.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I32/79

[1] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[2] Torre LA，Siegel RL，Jemal A. Lung Cancer Statistics [J]. Adv Exp Med Biol，2016，893：1-19.
[3] Walter AO，Sjin RT，Haringsma HJ，et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC [J]. Cancer Discovery，2013，3（12）：1404.
[4] Wang CD，Wang XR，Wang CY，et al. Relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma [J]. Asian Pac J Trop Med，2015，8（3）：249-252.
[5] Fukuoka M，Wu YL，Thongprasert S，et al. Biomarker analyses and final overall survival results from a phase Ⅲ，randomized，open-label，first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia （IPASS） [J]. J Clin Oncol，2011，29（21）：2866-2874.
[6] Hong MK，Laskin WB，Herman BE，et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett′s esophagus [J]. Cancer，2015，75（2）：423-429.
[7] Sun W，Yuan X，Tian Y，et al. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer [J]. J Hematol Oncol，2015，8：95.
[8] Wang H，Huang J，Yu X，et al. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer：a meta-analysis [J]. J Cancer Res Clin Oncol，2014， 140（11）：1901-1909.
[9] Haber DA. Activating mutations in the epidermal growth factor receptor underlie responsiveness of non-small cell lung cancer to the tyrosine kinase inhibitor Gefitinib [J]. Cancer Research，2005，65.
[10] Wu YL，Zhou C，Hu CP，et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations （LUX-Lung 6）：an open-label，randomised phase 3 trial [J]. Lancet Oncol，2014，15（2）：213-222.
[11] Sacher AG，Dahlberg SE，Heng J，et al. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer [J]. JAMA Oncol，2016，2（3）：313.
[12] Welsh J，Amini A，Kim ES，et al. Phase Ⅱ study of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer [J]. J Clin Oncol，2011，81（2）：2031.
[13] Midha A，Dearden S，McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology：a systematic review and global map by ethnicity （mutMapII） [J]. Am J Cancer Res，2015，5（9）：2892-2911.
[14] Pao W，Miller V，Zakowski M，et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib [J]. Proc Nati Acad Sci U S A，2004， 101（36）：13 306-13 311.
[15] Wu YL，Zhou C，Liam CK，et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer：analyses from the phase Ⅲ，randomized，open-label，ENSURE study [J]. Ann Oncol，2015，26（9）：1883.
[16] Huang HT，Chen L，Lu CX，et al. Clinical pathological significance of expression of Tspan-1，Ki67 and Cd34 in human lung cancer [J]. Acta Medica Mediterranea，2015， 31（6）：1175-1180.
[17] Romero Q，Bendahl PO，Fern? M，et al. A novel model for Ki67 assessment in breast cancer [J]. Diagn Pathol，2014， 9（1）：1-8.
[18] Li LT，Jiang G，Chen Q，et al. Ki67 is a promising molecular target in the diagnosis of cancer （review） [J]. Mol Med Rep，2015，11（3）：1566.
[19] Dingemans AC，Van AJ，Span S，et al. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer [J]. Lung Cancer，2001，32（2）：117-128.
[20] Li J，Chen L，Jiao SC，et al. Topoisomerase Ⅱ alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer [J]. BMC Cancer，2010，10（1）：621.